Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 195, Issue 1, Pages 1-15Publisher
SPRINGER
DOI: 10.1007/s10549-022-06665-6
Keywords
Triple-negative breast cancer; Immunotherapy; Checkpoint blockade; Clinical Trials; Atezolizumab; Pembrolizumab
Categories
Funding
- National Institutes of Health [K08-DE026500, U01-CA243075, F32-CA265232]
Ask authors/readers for more resources
Immunotherapy has shown promise in the treatment of TNBC, but responses are limited to a subset of patients. Combination chemoimmunotherapy approaches have been more successful, and pembrolizumab is approved for advanced TNBC in combination with chemotherapy.
Purpose Immunotherapy has started to transform the treatment of triple-negative breast cancer (TNBC), in part due to the unique immunogenicity of this breast cancer subtype. This review summarizes clinical studies of immunotherapy in advanced and early-stage TNBC. Findings Initial studies of checkpoint blockade monotherapy demonstrated occasional responses, especially in patients with untreated programmed death-ligand 1 (PD-L1) positive advanced TNBC, but failed to confirm a survival advantage over chemotherapy. Nonetheless, pembrolizumab monotherapy has tumor agnostic approval for microsatellite instability-high or high tumor mutational burden cancers, and thus can be considered for select patients with advanced TNBC. Combination chemoimmunotherapy approaches have been more successful, and pembrolizumab is approved for PD-L1 positive advanced TNBC in combination with chemotherapy. This success has been translated to the curative setting, where pembrolizumab is now approved in combination with neoadjuvant chemotherapy for high-risk early-stage TNBC. Conclusion Immunotherapy has been a welcome addition to the growing armamentarium for TNBC, but responses remain limited to a subset of patients. Innovative strategies are under investigation in an attempt to induce immune responses in resistant tumors-with regimens incorporating small-molecule inhibitors, novel immune checkpoint targets, and intratumoral injections that directly alter the tumor microenvironment. As the focus shifts toward the use of immunotherapy for early-stage TNBC, it will be critical to identify those who derive the most benefit from treatment, given the potential for irreversible autoimmune toxicity and the lack of predictive accuracy of PD-L1 expression in the early-stage setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available